2,291 reports of this reaction
2.3% of all BOSENTAN reports
#4 most reported adverse reaction
PULMONARY ARTERIAL HYPERTENSION is the #4 most commonly reported adverse reaction for BOSENTAN, manufactured by Actelion Pharmaceuticals US, Inc.. There are 2,291 FDA adverse event reports linking BOSENTAN to PULMONARY ARTERIAL HYPERTENSION. This represents approximately 2.3% of all 98,401 adverse event reports for this drug.
Patients taking BOSENTAN who experience pulmonary arterial hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY ARTERIAL HYPERTENSION is a less commonly reported adverse event for BOSENTAN, but still significant enough to appear in the safety profile.
In addition to pulmonary arterial hypertension, the following adverse reactions have been reported for BOSENTAN:
The following drugs have also been linked to pulmonary arterial hypertension in FDA adverse event reports:
PULMONARY ARTERIAL HYPERTENSION has been reported as an adverse event in 2,291 FDA reports for BOSENTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY ARTERIAL HYPERTENSION accounts for approximately 2.3% of all adverse event reports for BOSENTAN, making it a notable side effect.
If you experience pulmonary arterial hypertension while taking BOSENTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.